Lecture Notes

**Lecture Coverage:**
- Cancer Immunoediting
- Cancer Immunosurveillance
- Cancer Immune Escape

---
#### **Cancer Immunoediting**
- Dynamic Process explaining the dual role of the immune system suppressing and/or promoting tumor growth
	- Made up of 3 Phases:

| Phase       | Description           |
| ----------- | --------------------- |
| Elimination | Surveillance > Escape |
| Equilibrium | Surveillance ≈ Escape |
| Escape      | Surveillance < Escape |


#### **Cancer Immunosurveillance**
- Combination of Anatomical Barriers, Innate & Adaptive immunities

**Innate Immunity**

|                    Cell Type                     |                         Receptors                          |                                                                            Means of Tumor Recognition                                                                            | Function                                                                                                                                                                                                                                                   |
| :----------------------------------------------: | :--------------------------------------------------------: | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------: | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
|     <abbr Title="Dendritic Cell">DC</abbr>s      | <br><abbr Title="Pattern Recognition Receptors">PRR</abbr> | <br>Tumor-derived <abbr Title="Damage-Associated Molecular Patterns">DAMP</abbr>s (e.g. <abbr Title="Heat Shock Proteins">HSP</abbr> & <abbr Title="Mitochondrial">mt</abbr>DNA) | Phagocytosis & Absorb Antigen<br>Present Antigen to CD4<sup>+</sup> & CD8<sup>+</sup> T Cells                                                                                                                                                              |
|                   Macrophages                    |                             ^                              |                                                                                        ^                                                                                         | Phagocytosis                                                                                                                                                                                                                                               |
| <br><abbr Title="Natural Killer">NK</abbr> Cells |                         <br>NKG2D                          |                                                  <br><abbr Title="MHC I Polypeptide-Related Sequence A & B">MICA & MICB</abbr>                                                   | Induce Lysis: <abbr Title="Interferon">IFN-γ</abbr>, Granzyme B & Perforin<br>Induce Apoptosis: <abbr Title="TNF (Tumor Necrosis Factor) Related Apoptosis-Inducing Ligand">TRAIL</abbr><br><abbr Title="Antibody Dependent Cell Cytotoxicity">ADCC</abbr> |

**Adaptive Immunity**
- Antigen Specific Recognition, (In)direct Killing, Long-Term Memory Protection

|            Cell Type             |                              <                               | Means of Tumor Recognition | Function                                                                                                           |
| :------------------------------: | :----------------------------------------------------------: | :------------------------: | ------------------------------------------------------------------------------------------------------------------ |
| <br><br><br>Conventional T Cells |         CD4<sup>+</sup><br><font size=2>(Th1)</font>         |         APC MHCII          | CD8<sup>+</sup> Activation, Expansion & Memory<br>- Through Cytokines (IL-2) & Co-Stimulatory Signals (CD40-CD40L) |
|                ^                 |         CD4<sup>+</sup><br><font size=2>(All)</font>         |         APC MHCII          | Differentiate into effector subsets upon Activation<br>Ensure Optimal Responses by other Lymphocytes               |
|                ^                 |                       CD8<sup>+</sup>                        |       APC MHCI / Th1       | Direct Cytotoxicity → <br>Differentiate into Memory Cell / Functional Exhaustion                                   |
|    <br>Unconventional T Cells    | <abbr Title="Invariant Natural Killer T Cells">(i)NKT</abbr> |      APC / Tumor CD1d      | Tumor Cytolysis (More Effective on Metastasis)<br>Regulation of other Lymphocytes                                  |
|                ^                 |                             γδT                              |            APC             | Broad Functional Plasticity (e.g. Direct Cytotoxicity)                                                             |
|           <br>B Cells            |                           All<br>                            |            APC             | Tumor Antigen Presentation<br>Cytokine Release                                                                     |
|                ^                 |                            Plasma                            |   APC / CD4<sup>+</sup>    | Secrete IgG1 Antibodies → Facilitate ADCC & Phagocytosis                                                           |

**Cancer Immunity Cycle**

| Stage                        | Description                                                                                                                                                                                                                                                                                                                                                                                     |
| ---------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| <br>Antigen Tumor Release    | Tumor Release Antigen in the form of <abbr Title="9-22 A.A. Long Antigenic Fragments">Epitopes</abbr><br>- <abbr Title="Tumor Specific Antigen (Not normally present in human)">TSA</abbr>: <abbr Title="Mutated Antigen">Neoantigen</abbr> / Viral Antigen<br>- <abbr Title="Tumor Associated Antigen (Normally present in human)">TAA</abbr>: Overexpressed / Cancer-Testis / Differentiation |
| <br><br>Antigen Presentation | Antigen presented on APC surface as <abbr Title="Human Leukocyte Antigen, The MHC of Humans">HLA</abbr>-Epitope Complex for T Cell Activation<br>- MHCI: CD8<sup>+</sup> (<abbr Title="When APC is infected & can synthesize tumor antigen">Endogenous Pathway</abbr>)<br>- MHCII: CD4<sup>+</sup> (<abbr Title="APC endocytose & present tumor antigen">Exogenous Pathway</abbr>)              |
| ^                            | Cross-Presentation: Switch from Exogenous to Endogenous Pathway<br>- Can activate CD8<sup>+</sup> without APC infection ([[Lecture 3 - Innate Immunity#**Bridging between Innate and Adaptive Immunity**\|SBMS3201 Lecture 3]])                                                                                                                                                                 |
| <br>T Cell Activation        | By 3 Key Signals:<br>- HLA-Epitope-TCR Signal<br>- Co-stimulatory Signals (CD28-80 / CD28-86)<br>- Cytokine Signals: Determines T Cell Fate                                                                                                                                                                                                                                                     |
| T Cell Migration             | CD8<sup>+</sup> Migrate to TME through Blood / Lymphatic Vessels                                                                                                                                                                                                                                                                                                                                |
| T Cell Infiltration          | CD8<sup>+</sup> <abbr Title="Cell Migration in response to Chemical Stimuli">Chemotaxis</abbr> into TME through Chemokine Receptors                                                                                                                                                                                                                                                             |
| T Cell Recognition           | CD8<sup>+</sup> recognize tumor cells via TCR-MHCI-Epitope Complex<br>- Tumor MHCI assembled in ER via proteasome-degraded peptides transported by <abbr Title="Transporter Associated with Antigen Processing">TAP</abbr>                                                                                                                                                                      |
| T Cell Tumor Killing         | CD8<sup>+</sup> Induce lysis & apoptosis on tumor cells                                                                                                                                                                                                                                                                                                                                         |
| T Cell Fate                  | Differentiate into Memory / Exhausted T Cells                                                                                                                                                                                                                                                                                                                                                   |


#### **Cancer Immune Escape**
- Evolution of Cancer Cells / Microenvironment to Avoid Immunosurveillance
	- Hinders various stages of the Cancer Immunity Cycle

**Loss of Immunogenicity**
- Evolution to lack / mutate immunogenic tumor antigens → Avoid recognition
- Defects in MHCI-Epitope Pathway: Downregulation of MHCI Heavy Chain / Proteasome / TAP

**Impaired T Cell Infiltration**
- Altered Chemokine Expression: Prevent Chemotaxis

**Tumor Immunosuppressive Microenvironment**
- Suppression by Immune Checkpoints
	- Ligands of <abbr Title="Co-inhibitory B7-CD28">Immune Checkpoints</abbr> can induce T cell functional exhaustion
		- <abbr Title="Programmed Death">PD</abbr>1 & PD1L
		- <abbr Title="Cytotoxic T Lymphocyte Antigen 4">CTLA-4</abbr>
- Suppression by Tumor Cell Crosstalk
	- Death Signals can induce CD8<sup>+</sup> cell Apoptosis
		- FAS / TRAIL Ligands
	- Cytokines / Metabolites can inhibit CD8<sup>+</sup> cell antitumor functions
		- <abbr Title="Transformation Growth Factor">TGF</abbr>β, IL-10
		- Cholesterol
	- Cytokines / Metabolites imbalance can inhibit DC Differentiation / Maturation
		- <abbr Title="Cyclooxygenase 2">COX2</abbr>
		- <abbr Title="Prostaglandin E2">PGE2</abbr>
- Suppression by Immunosuppressive Cells
	- Treg
	- MDSC & TAM
	- Immunosuppressive Properties of Treg, MDSC & TAM

| Properties                       | Treg                                                                                                                                                                                                          | MDSC & TAM                |
| -------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------- |
| Origin                           | Heterogenous Population of CD4<sup>+</sup> Cells<br>- With CD4<sup>+</sup>/ CD25<sup>+</sup>/ <abbr Title="Protein that attaches to DNA & Regulate immunity gene activity">Foxp3</abbr><sup>+</sup> Phenotype | Common Myeloid Progenitor |
| Inhibitory Cytokine Production   | Yes                                                                                                                                                                                                           | Yes                       |
| Inhibitory Metabolite Production | No                                                                                                                                                                                                            | Yes                       |
| Suppression of DC                | Yes                                                                                                                                                                                                           | No                        |
| Inducing Cell Death              | Cytolysis (Perforin & Granzyme A/B)                                                                                                                                                                           | Apoptosis (Fas)           |
| Metabolic Disruption             | Affect Receptor & cAMP activities                                                                                                                                                                             | Amino Acid Depletion      |
